As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

A single interactive map for all that is known on COVID-19

Dr. Anna Niarakis, teaching researcher in bioinformatics and computational systems biology at the Genopole laboratory GenHotel (University of Évry) is one of the four coordinators for the international COVID-19 Disease Map project.
COVID-19 Disease Map >
Covid-19 D Covid-19 D

Responding to a call made by the Disease Maps community, close to 200 scientists from 100 institutions in 24 countries are participating in the project.
The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

This major collaborative project has resulted in a platform that is available to the entire scientific community and constantly evolving as knowledge on COVID-19 advances. Presented in the form of an interactive map, the platform compiles all available data on virus/human-host molecular interactions and their roles in the complex mechanisms of the disease: infection processes, biological pathways and affected cells, viral proliferation, inflammatory responses, etc. In this way, the contributors to the project hope to more effectively increase our understanding of COVID-19 and accelerate the development of diagnostics and therapeutics.

As the project’s modeling coordinator, Anna Niarakis will deploy the dynamic modeling tool she developed at Inria within the GenHotel laboratory originally for rheumatoid arthritis. That tool enables virtual testing of the effects of perturbations on disease course, particularly viral proliferation, cellular death and inflammation. By crossing such analyses with therapeutics databases, it becomes possible to identify drug candidates.

Logo - Covid-19 Disease Map

COVID-19 Disease Map

The COVID-19 Disease Map enables visual explorations and computational analyses of the molecular mechanisms involved in SARS-CoV-2 viral entry and multiplication, virus/host interactions, immune responses and cell recuperation. The main challenge it faces is to associate rapidity and reliability in the race against the unprecedented COVID-19 pandemic. This includes not only the exhaustive collection of data, but also the verification of the reliability of those data, which are often taken from increasingly present preprint articles. Bioinformaticians organize and explore those highly informative data then biologists, virologists and clinicians verify models.

COVID-19 Disease Map: providing all competencies

The active participation of close to 200 scientists provides all the competencies needed for a better understanding of COVID-19:

  • the molecular and clinical aspects of the pathology;
  • molecular interaction characterizations and systems biology schemas illustrating disease mechanisms;
  • medical literature reviews;
  • the integration of diverse databases and bioinformatics expertise;
  • computational modeling to analyze disease-associated perturbations via systems biology approaches.

The initiative: mutualize expertise and energy to meet the challenges of COVID-19

The COVID-19 Disease Map project is an interdisciplinary effort involving researchers and clinicians with complementary competencies to rise to the challenge of COVID-19. It benefits from the participation of renowned international scientific groups that strengthen the project in a wide range of domains. The various project orientations progress together thanks to the volunteer work and enthusiasm of the project’s community.

The international scientific community’s massive participation in the project stands as a positive signal for the future, wherein all can indeed come together for a shared cause, achieve concrete results and accelerate the fight against a sinister disease.

The GenHotel lab actively engaged in the battle

Four people are in charge of managing and advancing the COVID-19 Disease Map project: Dr. Marek Ostaszewski (University of Luxembourg), Dr. Alexander Mazein (University of Luxembourg), Dr. Inna Kuperstein (Institut Curie) and Dr. Anna Niarakis (University of Évry, Paris-Saclay University).

Dr. Anna Niarakis is an associate professor at the University of Évry–Paris-Saclay and a researcher at GenHotel, the Genopole laboratory for complex diseases and rheumatoid arthritis. From day one of the project, she has been actively involved in several axes:

  • project conception and management;
  • map construction;
  • development of data analysis pipelines and dynamic modeling.

She has teamed with Vidisha Singh, PhD student at GenHotel and Sara Sadat Aghamiri, Inserm engineer at the Saint-Louis Hospital and GenHotel to construct graphs of disease-associated biological mechanisms using SBGN (Systems Biology Graphical Notation Scheme) notation and MIRIAM (Minimum Information Required in the Annotation) identifiers.
Their team deploys competencies to construct large-scale molecular maps, including the recently-published rheumatoid arthritis map. (show map).

Dr. Niarakis also coordinates bioinformatics analysis and computational modelling for the COVID-19 Disease Map project. A program called CasQ, which she developed with Sylvain Soliman of INRIA-Saclay’s Lifeware team and recently published in Bioinformatics (read the article), is used in that setting to produce discrete models executable at a large scale from molecular maps.

The COVID-19 Disease Map objectives in brief:

The COVID-19 molecular map will:

  1. serve as a high-quality, complete, easily-accessed resource with human curation;
  2. provide integrated solutions for textual exploration and artificial-intelligence assisted data exploration for improved content conservation and enrichment;
  3. ensure free access to reusable and interoperable content that interfaces with other databases and data referentials;
  4. provide a multi-omic data analysis platform with assisting disease maps, drug repurposing information and clinical data integration systems;
  5. furnish a mechanistic model for the development of computer models for in silico simulations of combined perturbations (KO, KI) and predictions of novel therapeutic targets;
  6. act as a community hub enabling the development of state of the art technologies for tomorrow’s medical challenges.

To learn more about the COVID-19 Disease Map project

Click here if you would like to contribute to the project

Article posted on 5 May 2020


The latest news

Hélène Virasith, Program manager à Genopole, a accompagné trois startups génopolitaines Nutropy, AuraLIP et Onima au salon Futur Food Tech de Chicago - Juin 2024

Genopole at the Futur FoodTech 2024 – Chicago

Genopole was in Chicago on June 17 and 18 for the Future Food Tech conference. Genopole® accompanied three of the biocluster's companies developing more sustainable food: Nutropy, AuraLIP and Onima. This was an opportunity for them to get noticed by major US groups and investors, and to gain an insight into North American market trends.

La délégation Genopole à BIO USA 2024

Genopole at BIO International 2024

The Genopole team at the BIO International Convention in San Diego pursued three main objectives: promote Genopole accompaniment to attract new talent, highlight biocluster companies and gather information on market and regulatory tendencies.

Visite de la délégation

Genopole and the Netherlands: together to accelerate the development of alternative proteins

Genopole welcomed a Dutch delegation of close to 20 company representatives and alternative proteins researchers. The objective of the visit was to explore possibilities for research and business partnerships aimed at the development of new foods capable of meeting the future's nutritional, environmental, health, business and gustatory demands.

©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Integrating informatics, structural biology and in vivo exploration for the discovery of new medicines

SABNP & Synsight: discovery of new medicines

SABNP and Synsight have validated an integrated, drug discovery approach uniting informatics, structural biology and in vivo exploration.

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

Lambe - Genopole's laboratory

Lambe: Detecting coagulation biomarkers with a natural nanopore

The Lambe laboratory showed proof of concept for a coagulation biomarker detection technology based on a natural nanopore.

Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Genoscope: Biomanufacturing with bacteria

A team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Conceived by the Genomics Metabolics Unit, Galaxy-SynBioCAD accelerates biological design and engineering for the production of next generation chemical compounds.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

View all >
With the support from
Région île de France